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Patients with cystic ﬁbrosis (CF) are aﬄicted with many symptoms but the greatest challenge is the ﬁght against chronic bacterial
infections, leading to decreased lung function and ultimately death. Our group has recently found reduced levels of ceramides
in CF patients and mice. Ceramides are sphingolipids involved in the structure of cell membranes but also participate in the
inﬂammatory response, in cell signalling through membrane microdomains (lipid rafts), and in apoptosis. These characteristics
of ceramides make them strong candidates for therapeutic intervention in CF. As more studies have come to evaluate the role of
ceramide in CF, conﬂicting results have been described. This paper discusses various views regarding the potential role of ceramide
in CF, summarizes methods of ceramide detection and their role in the regulation of cellular and molecular processes.
1.Introduction
Cystic ﬁbrosis (CF) is the most common autosomal recessive
disorder found in populations of European descent. It
is estimated that 70,000 individuals live with the disease
around the world (see http://www.cﬀ.org/AboutCF/)w i t h
70% of patients having the ΔF508 mutation. The disease is
caused by a mutation in the Cystic Fibrosis Transmembrane
Conductance Regulator (CFTR) gene which encodes for a
chloride channel. Mutations in the gene cause decreased
chloride transport out of the cell; consequently, there is
an increased absorption of sodium and reduction in the
airway surface liquid. Mucociliary clearance is thus impaired
creating a perfect environment for bacterial colonization.
Phenotypes of CF are recurrent and chronic pulmonary
infections, decreased lung function, pancreatic insuﬃciency,
diabetes, meconium ileus, infertility in males, osteoporosis,
and fatty acid defects [1–4].
Current therapies for CF include aerosolized antibiotics
such as tobramycin, recombinant human DNase such as
dornase alfa for improved mucus clearance, hypertonic
saline for increases in airway surface liquid, and nons-
teroidal antiinﬂammatory drugs (NSAIDs) like Ibuprofen
to decrease the inﬂammatory response. Other antibiotics
such as azithromycin are commonly used to ﬁght P. aerug-
inosa infections [5]. Bronchodilators are also commonly
prescribed to improve breathing [5]. CF patients take a
combination of drugs to improve or maintain lung function
not to mention vitamins and pancreatic enzymes and, at
times, insulin for pancreatic insuﬃciency [6] and diabetes
[7]. Despite prophylactic treatments, CF patients still suﬀer
from chronic infections and exacerbations which have
psychological impacts and ultimately impact the progression
of the disease.
Recently,wehavedescribedanewcharacteristicobserved
in CF patients and mice. Concentrations of ceramide were
found to be reduced in plasma of CF patients and mice as
well as CF-related organs in mice: lungs, pancreas, and ileum
[8]. Subsequent studies have investigated the importance
of ceramide in the context of CF indicating that it might
be a potential target for new therapies. However, contrary
to our data, certain groups have reported elevated levels2 Journal of Lipids
of ceramide in CF tissues from patients and mice. These
contradicting results have shed light on the potential role
of ceramide in CF; however, they also bring attention to
the issues surrounding the diﬀerent methods of ceramide
analysis. This paper will examine why ceramide should be
considered a key player in the symptoms of CF disease.
Importance will be placed on the methodologies used to
analyze ceramide and also the various models used to study
ceramide in CF.
2. Ceramides
2.1. Roles, Synthesis, and Structure. Ceramides are molecules
from the sphingolipid family. They are known to be involved
in membrane rigidity and permeability, apoptosis and can
act as second messengers signalling to Cathepsin D, PKC,
PP2A, and c-Raf [9]. In the cell membrane, ceramides
are components of microdomains (lipid rafts) which are
important in transmembrane signalling [10].
Therearetwopathwaysforceramidesynthesis(Figure 1).
The de novo pathway occurs in the endoplasmic reticulum
and begins with the conversion of serine and palmitoyl-CoA
to sphinganine by serine palmitoyl transferase. Ceramide
synthases then transform sphinganine into dihydroceramide
which is converted to ceramide by dihydroceramide desat-
urase. Alternatively, ceramide can be synthesized through
a recycling pathway with the conversion of sphingomyelin
to ceramide by sphingomyelinase (SMase) [9]. There are
several types of SMase categorized based on pH optima and
localization in the cell: acidic (aSMase), neutral (nSMase),
and alkaline (Alk-SMase) [11]. Generally a pH of 4.5–
5.0 is optimal for aSMase and it is localized mainly in
l y s o s o m a lc o m p a r t m e n t si nt h ec e l l sa sw e l la si nm e m b r a n e
microdomains (discussed later) in the cell membrane [12].
N e u t r a lS M a s e sh a v eap Ho p t i m ao f7 . 4[ 12]a n dc a nb e
located in the plasma membrane [13]. Alk-SMase is mainly
found to be expressed in the intestines [14]. Considering
that the deﬁciency in ceramides in CF can be corrected
by fenretinide and the induction of dihydroceramide, the
precursor to ceramide, can be detected [8], these ﬁndings
suggest that the de novo pathway involving the endoplasmic
reticulum is targeted by this drug in CF as it was described
before in the context of cancer.
Ceramides are deﬁned by the presence of a sphingoid
base in their backbone. A sphingoid base is the name given
to the carbon chain containing 2 to 3 OH groups and often
a double bond at carbon 4 present in sphingolipids [9].
All ceramides have a sphingoid backbone of 18 carbons;
however,theycandiﬀerinthenumberofcarbonsinthefatty
acidmoiety.Thesphingoidbackbonecontainsadoublebond
in ceramides which when removed forms dihydroceramide
(DHC) often indistinguishable from ceramide when using
methods based on the analysis of total ceramide levels [15].
Ceramides can also have other molecular modiﬁcations such
as the addition of glucose to obtain glucosylceramide and
galactosetohavegalactosylceramide[9].Thesemoleculesare
also metabolically active and while not speciﬁcally analyzed
inthestudiesthatwillbelaterdescribedlateron,theyremain
important members of the sphingolipid family.
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Figure 1: Synthesis pathway of ceramide. There exist two pathways
for ceramide synthesis: de novo pathway and recycling pathway. The
de novo pathway occurs in the endoplasmic reticulum while the
recycling pathway occurs in vesicular and cell membranes.
2.2. Detection of Ceramides. There are several issues to
consider when developing an appropriate methodology for
the analysis of ceramides. Phospholipids constitute approxi-
mately30%oflipidsincells[16].Thesemoleculesaresimilar
instructurethustheanalysisrequireshigh levelof speciﬁcity.
Ceramides alone represent only 1% of lipids present in the
cell [15]. Therefore, a sensitive and highly speciﬁc technique
must be utilized for an accurate analysis.
2.2.1. Diacylglycerol Kinase Assay. One of the most common
biochemical assays for ceramide detection involves the use
of diacylglycerol (DAG) kinase which can convert ceramide
to ceramide-1-phosphate. The assay quantiﬁes levels of
ceramides by incubating extracted lipids with [P32]A T Pa n d
DAG kinase and assessing the levels of [P32]c e r a m i d e - 1 -
phosphate. There are certain caveats with this method [17],
and there has been some question regarding the validity of
the results generated with this assay [18, 19]. The source
and amounts of the enzyme and ATP can alter the results
obtained. Additionally, an internal standard should ideally
be used to normalize the level of enzyme activity [15]. In
summary, proper care must be taken into consideration to
produce valid results [20], and ideally data should be veriﬁed
using a more sensitive technique.
2.2.2. Immunodetection. There exist two main antibodies
which have been employed in ceramide detection. A
monoclonal antibody clone 15B4 (Sigma-Aldrich, Oakville,
Ontario, Canada) was employed by our group using lipids
p u r i ﬁ e db yt h i nl a y e r e dc h r o m a t o g r a p h y( T L C )i na nE L I S A
assay [8] and by others in immunohistochemistry [21].
A polyclonal antibody, IgM-enriched mouse anticeramide
antiserum (Glycobiotech, K¨ ukels Germany, formerly
identiﬁed as MAS 0010) and more recently a monoclonal
anticeramide antibody (S58-9, same molecule as MAS 0010Journal of Lipids 3
sold without the addition of mouse serum, Glycobiotech),
has been used by some CF investigators [21, 22].
Both antibodies were evaluated and compared in a study
by Cowart and colleagues [23]. The study tested the aﬃnity
of the antibodies to speciﬁc species of ceramide using lipid
overlay assaysand it wasfoundthat eachantibody recognizes
diﬀerent species and both recognize dihydroceramide. The
monoclonal antibody (15B4) had stronger aﬃnities to C14
andC24ceramidethanthepolyclonal.Italsocouldrecognize
C16 albeit giving a weaker signal than the polyclonal anti-
body. It also recognized phosphatidylcholine. The polyclonal
antibody had a strong aﬃnity to C14 and C16 ceramides
but had low detection of C10 ceramide. No other cross-
reactivitywasobservedinthisstudyusinglipidoverlayassays
[23]. The Cowart study observed that variable results can
be obtained when using diﬀerent techniques to evaluate
antibody sensitivity. Depending on the epitope exposure,
the antibodies may also cross-react with other species of
sphingolipids. For instance, the authors specify that they did
not compare the antibodies in the context of ELISAs and
suggest that the recognition of ceramide species may diﬀer
using this method [23]. Another study was conducted to
speciﬁcally characterize the polyclonal antibody. The results
of dot blot assays showed that the antibody was speciﬁc
to long−chain ceramides found in the skin (ceramide-2
[N-acylsphingosine], ceramide-3 [N-acylphytosphingosine],
ceramide-5 [N-(alpha-hydroxy)acylsphingosine] [24]) ,C 1 4
and C16 ceramides, and C16-dihydroceramide [25]. Choles-
terol could also be detected with the antibody when present
in high concentrations in thin-layered chromatography
assays. Dot blot assays were used to characterize the mon-
oclonal antibody and it was found to detect weakly C16-
dihydroceramide and strong sphingomyelin [25]. Aﬃnities
to ceramides besides ceramide-1 ([N-(omega-acyloxy) acyl-
sphingosine] [24]), ceramide-2, ceramide-3 and ceramide-5,
C14, C16, and C16-dihydroceramide were not assessed with
the monoclonal antibody [25].
The studies using antibodies in ceramide quantiﬁcation
have used them in diﬀerent ways. Our group has used the
monoclonal antibody in ELISAs only after the ceramide
fraction was isolated from lipids using thin layered chro-
matography [8]. Other studies have used these antibodies for
immunohistochemistry detecting the amount of staining for
a designated area with computer software [21, 22].
In sum, data obtained using antibodies must be critically
evaluated and should be veriﬁed with the methods able to
assess the complete spectrum of detectable ceramide species
and not only selected species of ceramides.
2.2.3. Mass Spectrometry. With the development and reﬁne-
ment of separation techniques such as liquid and gas
chromatography (LC and GC) and mass spectrometry (MS),
an accurate analysis of ceramides is now possible. Using
an appropriate ionization technique and lipid extraction
methods, it is feasible to determine not only the concen-
trations of ceramides in a sample, but also to quantify the
amounts of the numerous ceramide species during each
analysis [16, 26–28]. High pressure LC (HPLC) is often used
as a primary separation of lipids extracted from a given
sample.Lipidspeciesofsimilarmolecularstructurewillelute
oﬀ the column at similar times. Upon entry into the mass
spectrometer, the electrospray ionization (ESI) method is
used to ionize molecules. It is a soft ionization technique
which is not likely to cause damage to the lipid molecules
andiscurrentlythefavouredmethodoflipidionization[29].
Finally, to distinguish between the various ceramide species,
the molecules undergo two MS analyses (tandem MS or
MS/MS) where molecules are selected based on their mass
to charge ratio or m/z. There are a few techniques used to
determine amounts of ceramide at this step.
The product ion analysis method involves the detection
of molecules of a speciﬁc m/z in the ﬁrst MS step (occurring
in the ﬁrst quadrupole or Q1). The molecules selected will
undergo fragmentation by gas collision in Q2. Finally in the
second MS step, the fragments generated will be analyzed
in Q3 which will scan diﬀerent m/z settings resulting in
a spectrum of fragments issuing from the precursor ions
selected for in Q1 [28].
The precursor ion analysis is the opposite of product ion
scan. The Q1 is set to scan a range of m/z, 500 to 670m/z,
to select for all ceramide species [27]. These molecules are
fragmented in Q2 and speciﬁc fragments are detected in
the second round of MS in Q3. Ceramide molecules will be
fragmented into two distinct parts: the sphingoid backbone
and the carbon chain of varying lengths [27]. In Q3, the
d e t e c t o ri ss e ta t2 6 4m/z and will only detect the sphingoid
backbone from the fragments generated in Q2. To analyse
sphingoidbackbonesofdihydroceramides,thedetectormust
be set at 266m/z [28].
Multiple reaction monitoring is an alternative to both
methods. Both Q1 and Q3 are set to detect speciﬁc m/z.O n l y
molecules which pass the speciﬁc settings will be detected
in the end. However, the analysis is not limited to only one
pair of precursor and product ions. The detection can be
repeated in a cycle which allows for more sensitive and rapid
quantiﬁcations [28].
There are a few issues to consider when using the MS/MS
technique. The most important step is the puriﬁcation
of lipids from the biological samples. Current methods
use the procedure established by Folch et al. [30]a n d
modiﬁed later by Bligh and Dyer [31] which use a 2:1
chloroform/methanol solution for extraction. Appropriate
internal standards should be used which will elute from the
LC columns and become ionized in a similar way as the
ceramides molecules. These standards should be ceramides
that do not occur naturally in biological samples such as
C12 [28] or a cocktail of standards (Avanti Polar Lipids,
Alabaster, AL, USA). To accurately quantify the amounts
of diﬀerent ceramide species, standard curves must be
generated and to be precise, one standard curve per analyte
should be generated [32]. The concentration of lipids in the
sample prior to analysis is also important to prevent lipid
aggregation which can occur when lipid concentrations are
high. The concentration of lipids is suggested to be below
100pmol of total lipids/μL[ 32].4 Journal of Lipids
2.2.4.Sphingolipidomics. Thep r evioust ec hniq uesinMS/MS
are incredibly accurate; however, they can only detect known
molecules. More recently, researchers have increased their
interest in assessing the full spectrum of lipids in a sample.
To this end, sphingolipidomics utilizes a shotgun approach.
Lipids are extracted to which is added an internal standard
for each lipid class. The lipid extraction from samples
is further reﬁned so that speciﬁc lipid classes can be
isolated even before separation methods come into play. The
acidic and basic properties of lipids are used to ionize to
either positive or negative ions. This step called intrasource
separation replaces the separation using LC in the previous
MS/MS methods. Before quantitation can occur, a fragment
ionuniquetoagroupoflipidsofinterestmustbefoundtobe
able to set the detector, for example, 264m/z for ceramides.
Finally, the lipids of a speciﬁc group can be quantiﬁed by
comparing to the internal standard for that group [32].
There are a few issues that have arisen with this method,
mainly that quantiﬁcation of lipids in low concentrations
can be compromised if signals overlap with those from more
abundant lipids. There is a lack of internal standards at
the moment for certain classes of lipids, which will limit
the power of lipidomics for those molecules [32]. Recently,
a survey of the lipidome from yeast using shotgun mass
spectrometry has revealed that about 95% of the lipidome
was covered using this approach [33].
3. Ceramide and Bacterial Infections
CF patients are plagued with chronic pulmonary bacterial
infectionswhicharetheleadingcauseofmortalityinCF.The
majority of infections are caused by Pseudomonas aeruginosa
although Staphylococcus aureus, Haemophilus inﬂuenzae, and
Burkholderia cepacia are also common pathogens isolated
from lungs of patients [34]. There are many factors in CF
lungs that facilitate the chronic presence of infections such
as increased inﬂammatory responses, thick layers of mucus,
abnormal cell signalling, and defective cell death. There are
many instances where ceramide could potentially play a role
in CF.
3.1. Ceramide and the Inﬂammatory Response. CF patients
are plagued with high levels of cytokines. In animal models,
these levels are triggered despite the absence of infection
[35]. It is however unclear whether the abnormal expression
of inﬂammatory genes precedes infection in patients. A
few studies have described higher levels of inﬂammation
in infants with CF [36, 37]a n do n es t u d yh a sd e s c r i b e d
high levels of cytokines in foetuses with diagnosed CF [38].
Hallmarks of increased inﬂammation in CF are mainly
higher levels of IL-1β [39], IL-6 [40], IL-8 [41], TNF-α,
while the antiinﬂammatory IL-10 was found to be reduced
in CF [39]. The transcription factor NF-κB responsible
for the transcription of cytokines has increased levels of
phosphorylation in CF [42]. CFTR was found to be a
negative regulator of NF-κB phosphorylation which would
explain higher activation of the transcription factor when
CFTR is nonfunctional [43].
Ceramides were shown to be generated under certain
stimuli such as UV, heat, cytokines, oxidative stress, and
LPS and in turn ceramide can regulate the expression of
cytokines. A study by Chiba and colleagues revealed that
ceramides can have diﬀerent eﬀects on cytokine expression
depending on the cell type. The pretreatment of 10μg/ml of
C8ceramidereducedtheexpressionofIL-5,IL-10,andIL-13
in mast cells in response to LPS stimulation while TNFα and
IL-6 levels were unaﬀected. C8 ceramide did however inhibit
TNFα and IL-6 in macrophages but did not alter IL-10 levels.
In both cell types, the addition of C8 ceramide inhibited the
transcription of cytokines in response to LPS; however, the
inhibited cytokines were diﬀerent per cell type [44]. Results
comparing cytokine expression between aSMase deﬁcient
mice and normal controls showed a 10- to 15-fold increase
in serum TNFα following LPS administration in aSMase-
KO mice. In peritoneal macrophages isolated from aSMase
deﬁcient mice, the supplementation with 30 and 60μMo f
C2andC16ceramidewasabletonormalizeTNFαexpression
following stimulation with LPS [45].
IL-8 expression is mainly induced by NF-κBw h i c hi n
turn is activated by TNFα, among other mediators, and also
involves the activation of the MAPK pathway. Ceramides
were shown to activate protein phosphatase 2A (PP2A)
[46], a regulator of both NF-κB and MAPK pathways.
Using human alveolar epithelial cells, Cornell and colleagues
have demonstrated an increase in IL-8 levels when PP2A is
inhibited. The authors found that PP2A inhibition increases
the signalling through the MAPK pathway by prolonging the
activation of JNK, p38, and ERK and enhances the stability
of IL-8 mRNA. Similarly, inhibition of ceramide synthesis
led to a reduction in PP2A activation and consequently
an increase of IL-8 levels. The authors concluded that
ceramides are needed to activate PP2A in order to control
and, consequently, down regulate expression of IL-8 [47].
A recent study demonstrated that activation of p38
MAPK in lungs of CF patients is greater compared to
non-CF controls. Following exposure to P. aeruginosa,c e l l s
expressing the ΔF508 mutation experienced a much greater
increase in IL-6 compared to cells expressing normal CFTR
due to the overactivation of p38 MAPK [40]. Additionally,
decreases in ceramide were found to induce activation of
p38 MAPK which resulted in increased IL-6 production.
Treatment of alveolar epithelial cells with C6 ceramide
prevented the increase in IL-6 [48].
The results of these studies demonstrate the importance
of ceramide in regulating excessive inﬂammatory responses
and that a reduction in ceramide levels can result in an
uncontrolled production of cytokines which is resolved by
supplementation of ceramide. Additionally, the role of the
recycling pathway in ceramide generation following LPS
stimulation seems to be a key component to the response to
infections.
Azithromycin, a macrolide currently used to treat CF
patients, has been shown to improve clinical symptoms of
CFsuchaslungfunction,improvementinbacterialclearance
and attenuation of inﬂammation. While the mechanism of
this drug is still under investigation, it was found recently
that it induces expression of certain inﬂammatory genes andJournal of Lipids 5
those involved in the lipid pathways. In particular, certain
genes involved in the cholesterol pathway were induced.
An older study demonstrated that total cell phospholipid
content was increased following azythromycin treatment of
primary ﬁbroblasts [49] suggesting that manipulation of
phospholipids may beneﬁt the outcome of infections in CF.
3.2. Ceramide and Signalling Response to P. aeruginosa.
Signalling following infection occurs mainly through Toll-
like receptors (TLR) found in the plasma membrane. TLR-
4 is a receptor for lipopolysaccharide (LPS) found on the
surface of gram negative bacteria. TLR-4 expression was
found to be reduced in CF patients; however when the
CFTR defect was corrected in epithelial cells, higher levels
of TLR-4 were detected on the cell surface [50]. TLRs are
located at the cell surface in lipid rich clusters termed
microdomains. Membrane microdomains, also known as
lipid rafts, are lipid aggregates in plasma membranes com-
prisedofcholesterol,sphingolipids,andphospholipids.They
are involved in signal transduction by forming platforms for
receptors activated by their ligands. Microdomains spatially
organize proteins and protect them from enzymes which
could prevent downstream signalling (e.g., phosphatases)
[10]. Kowalski and Pier described the presence of CFTR
in membrane microdomains. They postulated that under
normal situations, CFTR is a receptor for LPS and induces
the internalisation of P. aeruginosa, the induction of the
inﬂammatory response, apoptosis and, during infection
with P. aeruginosa, the presence of CFTR increases in
microdomains. The ΔF508 mutation in CFTR prevents the
localisation of CFTR into the microdomains and bacterial
infection is not cleared [51]. Another member of lipid
microdomains is caveolin-1 which is involved in endocytosis
and cell signalling [52]. When caveolin-1 KO mice were
infected with P. aeruginosa, increased bacterial colonization
was observed compared to WT mice with higher mortality
rates indicating that caveolin-1 is an important component
in ﬁghting infection [52]. Few studies have been conducted
to elucidate the role of caveolin-1 in CF. One study has
observed that caveolin-1 colocalizes with CFTR and it
was found to be increased in CFTR-deﬁcient macrophages
inducing an inﬂammatory phenotype [53]. In sum, the
components of microdomains in CF seem to be abnormal,
possibly leading to defects in bacteria clearance.
Ceramides were found to stimulate TLR-4. Following
the addition of multiple doses of exogenous C2 and C6
ceramides up to 15μM, IL-8 was found to be increased in
human embryonal kidney cells while cells defective for TLR-
4 expression did not display any increase in IL-8 levels. The
increases were dose dependent and maximum expression of
IL-8 was found following treatment with 1.5μM C2 and C6
ceramides. Interestingly, IL-8 levels were reduced at higher
dosesofceramidetreatment.TheseresultsindicatethatTLR-
4 expression is necessary for IL-8 induction by extracellular
ceramides. The molecular mechanism regulating the induc-
tion of TLR-4 activation by extracellular ceramide was found
to diﬀer from that of LPS as TLR-4 activation by ceramide
was found to be CD14 independent [54].
A study by Grassme and colleagues showed the impor-
tance of ceramide in membrane microdomains and infec-
tions with P. aeruginosa. The bacteria were shown to interact
with sphingolipid membrane platforms following tracheal
infection of mice. The disruption of lipid microdomains
prevented P. aeruginosa-induced apoptosis and induced a
100-foldincreaseofIL-1βgeneexpressioncomparedtowhen
microdomainsremainedintact.WhenaSMasewasinhibited,
human nasal epithelial cells failed to internalize the bacteria
and IL-1β release was increased 10-fold compared to when
aSMase was active [55]. The addition of C16 ceramide was
able to correct the defects seen with aSMase inhibition;
internalization, cytokine secretion, and apoptosis returned
to normal [55]. This important study demonstrated the role
of ceramide in regulating the downstream eﬀects of bacterial
infections and gives insight into potential abnormalities in
ceramide levels in CF.
3.3. Disregulation of Apoptosis. It is postulated that cellslack-
ing functioning CFTR display defective control of apoptosis
[39, 56]. P. aeruginosa infection of wild-type epithelial cells
was found to induce apoptosis, bacterial internalization, and
caspase-3 and -6 activation, while infection of CFTR defec-
tive cells did not result in apoptosis [57]. One hypothesis
is that CFTR is a transporter of glutathione, an important
antioxidant able to protect cells against excessive oxidative
bursts. During apoptosis, glutathione is exported out of the
cell via CFTR to allow an oxidative stress-induced cell death.
In CF, increased levels of intracellular glutathione inhibit the
induction of apoptosis. Interestingly, glutathione was found
to inhibit nSMase preventing the generation of ceramide
following oxidative stress. It has been postulated that low
levels of ceramides prevent the completion of apoptosis even
when high DNA fragmentation can be observed [58].
Ceramides are important messengers in the control of
cell death. They activate signalling cascade of proapoptotic
molecules such as Akt, Bcl-2, pRB, PKCα and in some cell
types can activate Raf kinase and JNK [59]. In leukemia cells,
increases in TNFα can cause DNA fragmentation leading
to apoptosis. The addition of C2 ceramide induced DNA
fragmentation similar to the one observed in response to
TNFαincreases[60].Manystudiesinoncologyhaveinvolved
the modulation of ceramide levels to induce apoptosis [61–
63]. Increases in apoptosis of various tumour cells were seen
following the treatment of mice with ceramide analogs [64].
Fenretinide treatment was used in cancer studies due to
its known induction of apoptosis by increasing intracellular
ceramide levels [65]
It was shown that diﬀerent species of ceramide were
generated following the induction of B-cell receptors leading
to apoptosis. C16 ceramide levels were increased within 6
hours after apoptosis induction, while C24 levels were found
to peak much later, between 12 to 24 hours after apoptosis
induction, when caspases became activated [66]. Following
TNFα-induction of apoptosis, only one ceramide species,
C16, was found to be induced in hepatocytes. Inhibition of
ceramide induction by blocking aSMase activity was shown
to protect cells from apoptotic cell death. Apoptosis was also
reduced in aSMase KO mice [67].6 Journal of Lipids
4. Ceramide and Disease
The role of ceramide has been investigated in the context
of various diseases. In oncology, the role of ceramide as an
inducer of apoptosis has been exploited to kill tumour cells
in neuroblastoma [68], breast cancer [69], head and neck
cancer [70], and colon cancer [71]. Defects in aSMase have
been shown to cause Niemann-Pick disease, a progressive
neurodegenerative disorder. Knock-out mice for smpd1, the
gene encoding for aSMase, were found to be resistant to
radiation, apoptosis and TNF-α due to the reorganization
of membrane microdomains following the disruption of
ceramide, sphingomyelin, and cholesterol [72]. Interestingly,
following infection with P. aeruginosa, 90% of knock-out
(KO) aSMase mice died while the control mice were able to
clear the infection [55].
The role of ceramides has also been studied in other
neurodegenerative diseases such as amyotrophic lateral scle-
rosis (ALS) where an accumulation of the sphingolipid
was observed in spinal cords of patients and mice. The
current hypothesis is that ceramide levels are high due to
overactivation of the de novo pathway of ceramide synthesis
[73]. In Alzheimer’s disease, ceramide was linked to the
production of amyloid-β and to induce plaque formation.
Studies have found an upregulation of the enzymes respon-
sible for the synthesis of long chain ceramides such as
C18 and C24. Overexpression of aSMase was also observed
in certain parts of the brain [74]. IL-1β is known to be
involved in neurodegeneration at high concentrations in the
brain. These high levels were found to be mediated by high
levels of ceramide produced by the de novo pathway [75].
Increased levels of ceramide in blood plasma were found
to be associated with insulin resistance and diabetes. High
levels of C18, C20, and C24:1 were found in individuals
with type 2 diabetes while insulin resistance was associated
with low levels of C18, C20, C24, and C24:1 [76]. Gaucher’s
disease is a known monogenic disease of altered lipid
metabolism where glycosphingolipids are stored in tissues.
Studies have shown that increased macrophage activation
and tissue inﬂammation are involved in the pathology of the
disease [77]. Recently a lipidomic study revealed low levels of
ceramide in patients with Gaucher’s disease [77] indicating
that perhaps an impairment in one sphingolipid can alter the
metabolism of others.
5. Ceramide and Cystic Fibrosis
Contradicting ﬁndings have been published about ceramide
levels in cystic ﬁbrosis (CF). Table 1 summarizes the results
found about ceramide levels in CF. Our group has observed
reduced levels of ceramide in patients with CF. We have
analyzed ceramide levels in plasma samples from 10 patients
with CF and 10 healthy controls by HPLC/MS/MS. Our
results showed that speciﬁc species of ceramide were lower in
CFpatients:C14,C20:1,C22,C22:1,C24,andalsoDHC16.
When looking at the total levels, CF patients were found to
have an overall deﬁciency in ceramides [8]. We proceeded
to analyze total levels of ceramide in TLC puriﬁed ceramide
fractions using an ELISA based method in plasma of 58 CF
patients and 72 controls [4]. Our analysis of ceramide levels
in organs aﬀected by CF in our mouse model had also shown
defects in CF versus wild-type (WT) mice in plasma, lung,
ileum, and pancreas [8, 78]. The pulmonary bacterial load
of CF mice is 30-fold higher than WT mice three days post-
infection with P. aeruginosa. When treated with fenretinide,
a semisynthetic retinoid used to increase ceramide in cancer
studies [79–82], CF mice were able to clear infection to the
same degree as WT mice. Additionally, ceramide levels were
increased to the levels observed in WT mice in both plasma
and lungs. Mice treated with fenretinide also had a reduction
in gene expression of IL-1β and S100A8, genes involved in
the immune response to bacterial infections.
Vilela and colleagues demonstrated an increase in IL-8
levels in human tracheal epithelial cells with and without
CFTR expression following TNFα exposure. The study
showed that fenretinide treatment on cells lacking CFTR
expression reduced IL-8 levels after TNFα stimulation. Using
an HPLC method of ceramide detection, they also demon-
strated that intracellular levels of ceramide were increased
following fenretinide treatment in CFTR-deﬁcient cells [83].
Diﬀerent hypotheses could be made to explain why
ceramides are disregulated in CF. Various studies have
observed defects in SMases indicating that the recycling
pathway in CF is defective. In vitro studies by Yu and
colleagues have revealed an impairment in the response
of aSMase to P. aeruginosa in bronchial epithelial cells.
Following infection, S9 cells expressing CFTR experienced
an increase in intracellular ceramide concentrations whereas
IB3-1 CFTR-defective cells did not. Silencing aSMase before
infection caused an increase in IL-8 levels in S9 cells.
Similarly, when aSMase was added to IB3-1 cells, IL-8
levels were reduced suggesting that aSMase induction and
ceramide generation would ameliorate the regulation of
cytokineexpressioninthecontextofCF.Alowerincidenceof
cellular apoptosis was noticed following infection of CFTR-
deﬁcient cells in vitro and following P. aerugonisa infection
of mice which was improved with the addition of aSMase.
An increase in pulmonary ceramide levels was observed in
normal mice (C57BL/6) mice but not in CF mice (Cftrtm1unc-
TgN(FABPCFTR)) following oropharyngeal instillation of P.
aeruginosa; however, no diﬀerences were seen preinfection
[84].
Further in vitro studies by Noe and colleagues in
endothelial cell models revealed defects in ceramide
metabolism. Human microvascular endothelial cells respond
to H2O2 by increasing intracellular ceramide. Pretreating
the same cells with an inhibitor of CFTR (CFTRinh-172)
prevented the increase in ceramide levels. The authors linked
the defects in ceramide to the defects observed in apoptosis
whereby suggesting that the lack of apoptosis seen in CF may
be due to the defect in upregulating ceramide in response to
oxidative stress [85].
In contrast, studies by the Gulbins group found an
accumulation of ceramide in CF. Using ﬁrst two mouse
models of CF (Cftrtm1unc-Tg(FABPCFTR) and B6.129P2(CF/3)-
CftrTgH(neoim)Hgu), ceramide levels were quantiﬁed and by
liquid scintillation counting of ceramide spots run on TLCJournal of Lipids 7
Table 1: Summary of studies on ceramide in cystic ﬁbrosis.
Author Model used Method of analysis Results
Studies reportinglow levels of ceramide inCF
Vilela et al. [83] Human tracheal epithelial
cells HPLC
Ceramide was found to increase more in
cells lacking CFTR than those with
functioning CFTR following fenretinide
treatment
Guilbault et al. [8]
Plasma from CF patients, and
CF mice (B6. Cftrtm1unc)
Plasma from CF patients and
CF mice (B6. Cftrtm1unc)
HPLC/MS (13 species of ceramide
and 2 dihydroceramide species)
TLC followed by ELISA (antibody
clone 15B4)
↓ in C14, C20:1, C22, C22:1, C24,
DHC16 in patients
↓in total ceramide levels in patients and
mice (plasma and CF related organs).
Improvement in bacterial clearance when
ceramide is ↑ after fenretinide treatment
in CF mice following intratracheal
infection with P. aeruginosa
Correlation between ELISA and MS
techniques (P = .002, r = 0.541,
r2 = 0.293).
Saeed et al. [78] CF mice (B6. Cftrtm1unc) TLC followed by ELISA (antibody
clone 15B4)
↓in total ceramide levels in mice (plasma
and CF related organs).
Guilbault et al. [4]
Plasma from
CF patients
CF mice (B6. Cftrtm1unc)
TLC followed by ELISA (antibody
15B4)
↓ in total ceramide levels in patients and
C Fm i c e ,c o r r e l a t e dw i t hd e f e c t si nf a t t y
acids
Yu et al. [84]
Bronchial epithelial cells (S9
and IB3-1)
Cftrtm1unc-T g (FABPCFTR)
HPLC/MS
Ceramide levels are ↓ in cells lacking
CFTR compared to control cells during
infection.
Noe et al. [85] Human microvascular
endothelial cells
LC/MS (11 species of ceramide and
5 dihydroceramide species)
↑ in ceramide in response to H2O2 in cells
where CFTR is expressed.
When CFTR is inhibited, there is no
ceramide response.
Studiesreportinghigh levels of ceramide inCF
Teichgr¨ aber et al. [22]
CF mice (Cftrtm1unc-
Tg(FABPCFTR) and
B6.129P2(CF/3)-
CftrTgH(neoim)Hgu)
Human nasal epithelial cells
Explanted human lung tissue
Liquid scintillation counting
Immunoﬂuorescence (antibody
clone S58-9)
↑ in total ceramide levels in CF mice and
human cells
Blocking aSMase causes a ↓ in ceramide
Improvement in bacterial clearance in CF
mice when aSMase is inhibited and
ceramide levels ↓
Becker et al. [86]
CF mice (Cftrtm1unc-
Tg(FABPCFTR) and
B6.129P2(CF/3)-
CftrTgH(neoim)Hgu)
Immunoﬂuorescence (antibody
clone S58-9) DAG kinase assay
LC/MS (3 species of ceramide)
↑ in total ceramide levels (data
represented sum of C16, C18, and C20)
Inhibition of aSMase results in ↓ in
ceramide and in reduction in
susceptibility to intranasal infection with
P. aeruginosa
Ulrich et al. [87] Explanted human lung tissue Immunoﬂuorescence (antibody
clone S58-9)
↑ in ceramide in CF lungs
Zhang et al. [88] Alveolar mouse macrophages
DAG kinase assay
Immunoﬂuorescence (antibody
clone S58-9)
↑ in total ceramide in CF cells
↑ in ceramide following infection in WT
cells, not in CF cells
Brodlie et al. [21] Explanted human lung tissue
Immunoﬂuorescence (antibody
clones S58-9 and 15B4)
HPLC/MS (4 species of ceramide)
↑ in total ceramide (observed with
staining of antibodies)
↑ in C16, C18, C20. No change in C22.
Studyreportinghighandlow levels ofspeciﬁc ceramide species inCF
Hamai et al. [89] 16HBE14o(-) cells with or
lacking CFTR expression
TLC and liquid scintillation
counting
↑ in levels of DHC16, C22, C24, C26
↓ in levels of C18, C18:18 Journal of Lipids
plates compared to C16 ceramide. Additionally, immuno-
chemistry was used on paraﬃn embedded lungs using
the S58−9 antibody. The results showed elevated levels
of ceramide in vesicles of epithelial cells from CF mice
compared to the appropriate controls. Similar results were
obtained using epithelial cells obtained from CF patients by
nasalscrapingandlungtissueobtainedposttransplant.Their
study revealed that ceramide accumulated in intracellular
lysosomes. The authors attributed this accumulation to the
inhibition of aSMase in the lysosomes due to the impairment
in acidiﬁcation of the vesicles. The views on whether pH
regulation in vesicles is altered in CF are still conﬂicting.
Certain studies have shown that pH is abnormal in CF
vesicles [90] while others claim there are no diﬀerences [91,
92]. The authors treated mice with aSMase inhibitors which
resulted in the reduction of ceramide levels and improved
clearance of bacterial infections [22]. These results agree
with the studies by Yu and colleagues mentioned above.
When aSMase is not active, ceramide levels do not increase.
However, Yu and colleagues observed detrimental eﬀects
duringbacterialinfectionswhenaSMasefunctionisdefective
while the Gulbins study suggests that inhibition of aSMase
enablesincreasedsurvivalofmiceinfectedwithP. aeruginosa.
The same group studied the eﬀects of P. aeruginosa infection
in macrophages from WT mice and from macrophages
obtainedfromtheirCFmousemodels.UsingtheDAGkinase
assay revealed higher basal levels of ceramide in CF cells
compared to WT cells. Using an immunoﬂuorescence-based
method, they reported increased ceramide concentrations
in WT cells following bacterial infection but not in CF
macrophages. In response to the infection, WT cells had
increased clustering of ceramide in the plasma membrane
but this response was much reduced in CF cells [88].
An immunoﬂuorescence-based method was also used
in another study by the same group to evaluate the levels
of ceramide in alveoli from explanted lung tissue from
CF patients. Concurrent to their previous results obtained
with the same methods, they had seen higher staining with
anticeramide antibodies in CF tissue compared to donor
tissue [87]. No additional methods were used to corroborate
their data. Finally, in a fourth study, the group utilized three
methods of detection of ceramide: immunoﬂuorescence,
DAG kinase assay, and mass spectrometry. The authors
looked at three speciﬁc species of ceramide: C16, C18, and
C20. The levels of each of the three species were not speciﬁed
in the study but their sum was higher in lungs from their CF
mouse models compared to their controls [86].
The levels of ceramides in CF were assessed by UK
investigators using lung tissues from transplant patients
with CF and unused donor lungs. The authors used two
methodsofceramidequantiﬁcation:immunochemistrywith
the two antibodies (15B4 and S58−9) and HPLC/MS. The
immunochemistry results indicated that CF lung tissues
had higher median levels of staining compared to all
other lung tissue. The authors also found variability in
staining between the two antibodies although one was not
systematically staining more than the other. Ceramide levels
wereadditionally measuredbyHPLC/MSalthoughonlyfour
species of ceramide were analyzed. It was found that C16,
C18, and C20 were elevated in CF lung tissue while no
diﬀerence was observed for C22 [21].
Another study has shown a combination of the two
hypothesis ﬁnding elevated levels of certain species of
ceramide while others being reduced. Using TLC and liquid
scintillation counting, ceramide species were analysed in
16HBE14o(-) cells either expressing CFTR or the antisense
control gene construct. Four ceramide species were found to
be elevated (DHC16, C22, C24, C26) when no CFTR was
expressed while 2 species were reduced (C18 and C18:1)
compared to cells expressing CFTR [89].
The question remains why the studies report such diﬀer-
ent results. The ﬁrst suggestion is the use of diﬀerent models
either animal or cellular. Diﬀerent cell types may respond
diﬀerently to stress, and ceramides may act diﬀerently within
each cell type. There are many diﬀerent animal models used
in CF research with varying phenotypes. Many attempts to
produce an adequate model of CF which would reproduce
all phenotypes seen in patients failed due to the lack of
lung disease in mice. The ﬁrst attempts at generating a KO
mouse came from the University of North Carolina with
the disruption of exon 10 of Cftr with neomycin resistance
genes [93]. These mice had severe intestinal obstruction
but failed to produce any lung disease. A mixed genetic
background was at fault and researchers began to backcross
themicetoC57BL/6Jmice[94].Thesemicepr oduceastr ong
inﬂammatory pulmonary phenotype without having to
induceinfections.Reportshavedescribeddestructionoflung
structure [95], thick mucus lining the distal airways [95],
inﬁltration of inﬂammatory cells around the airways [35],
and increases in inﬂammatory gene expression in the lungs
[35]. Additionally, marked pathology in the pancreas was
observed with acinar atrophy and increased inﬂammation
[95]. Intestinal phenotypes were also observed with chronic
intestinal obstruction. These mice necessitate a liquid diet
(Peptamen, Nestle, Brampton, Ontario, Canada) not only to
avoidintestinalblockage,aphenotypewhichcanoccurinCF
patients, but to improve the absorption of nutrients without
having to supplement the diet with enzymes. This diet allows
CF mice to thrive and to maintain a healthy weight [96].
Other mouse models were generated to express speciﬁc Cftr
mutations such as ΔF508 [97], G551D [98], and G480C [99]
but ceramide levels have not been assessed in these models as
of yet.
To escape the need of special diets for CF mice, other
models were generated which could express Cftr locally in
the gut. The Cftrtm1unc-Tg(FABPCFTR) express CFTR in the gut
under control of a human fatty acid binding protein (FABP)
promoter. Although these mice show evidence of impaired
alveolar macrophage function without severe intestinal
pathology, there is however no description of chronic lung
disease in these mice (Jackson Lab site http://www.jax.org/).
The B6.129P2(CF/3)-CftrTgH(neoim)Hgu mouse model has low
levels of CFTR expression. These mice can survive on dry
pellet food. It is evident that diﬀerent mouse models present
diﬀerent phenotypes of CF disease (see review [100]). For
example, defects in fatty acids such as omega-3 and omega-
6 fatty acids have been shown in the B6.Cftrtm1unc KO
mouse [2, 4] but not in other models [101]. Some mouseJournal of Lipids 9
models have failed to demonstrate lung disease and it was
speculated that disease modiﬁer genes such as alternate
chloride channels could exist in certain mouse backgrounds
[94, 102]. It was veriﬁed that the B6.Cftrtm1unc KO mouse
does not express alternative chloride channels; however, this
has not been studied in most mouse models, including the
above described Cftrtm1unc-Tg(FABPCFTR) [94]. The latter
mouse model was generated using a mixed background of
129P3/J, C57BL/6, and FVB/NJ (see http://www.jax.org/).
The issue of diet has been brought up by the Gulbins
group asa point contention between in vivo ceramide studies
[22]. It has been suggested that Peptamen is responsible
for the reduced levels of ceramide by elevating cholesterol
levels which in turn inhibit aSMase activity [22]. However,
the authors overlooked the data from CF patients presented
in the same study. The cohort of CF patients assessed in
the study was not consuming Peptamen in their diet, were
monitored for their cholesterol levels, and none of the
patientswereplacedonacholesterolreducingdiet.Theeﬀect
of Peptamen on the levels of ceramide was analyzed in our
model of CF and WT mice and no inﬂuence of Peptamen
diet on the level of ceramide was observed [4]. Importantly,
these ﬁndings were assessed using LC/MS/MS analysis of
all detectable species of ceramides which demonstrated that
several ceramide species were impaired in CF (both in mice
and CF patients) [8]. This deﬁciency of speciﬁc ceramide
species was correctable by treatment with fenretinide in mice
[8], and we have recently obtained Orphan Drug status
approval by the US Food and Drug Administration (FDA)
for treatment with fenretinide of CF patients infected with P.
aeruginosa.
Recently, a genome-wide association study was per-
formed on 4,400 samples collected from ﬁve European pop-
ulations regarding their levels of circulating sphingolipids.
The results concluded that there are genetic variations in
genes involved in the sphingolipid metabolism indicating
that diﬀerent populations may have varying basal levels of
ceramide [103]. This is especially important clinically in CF
as genetic variation can aﬀect the severity of the disease, but
also in terms of research, diﬀerences seen in ceramide levels
between studies may be attributed to genetic diﬀerences of
the populations studied.
Another point of conﬂict can arise between the various
methods of ceramide analysis. Using antibodies in the
detection of ceramides can be misleading as they can bind to
a selection of ceramide species and lipids in general. While
immunohistochemistry oﬀers an opportunity to visualize
staining of tissues, one must be careful to interpret the
staining as pure ceramide detection since ceramides are not
puriﬁed from other lipids which might cross-react with the
antibodies. Using the antibodies in ELISAs necessitates an
initial separation of lipids by TLC from which the ceramide
fraction can be isolated. Without puriﬁcation, the cross-
reactivity of the antibodies prevents a reliable quantiﬁcation
of ceramides. While this assay can reduce costs for the
quantiﬁcation of ceramides for many samples, it cannot
provide data on the types of ceramide species nor the
concentration of each species present in the sample. DAG
kinase assays can be an inexpensive method for ceramide
analysis; however, only total levels of ceramide can be
assessed and once again, ceramide may not be the only lipid
quantiﬁed in the end. MS oﬀers unmistakable identiﬁcation
of various species of ceramides; therefore it represents the
best solution for accurate quantiﬁcation. Many are turning
to MS as a form of analysis; however, it is questionable
why certain studies chose to only look at a small subset of
species when it is possible to look at all the known forms of
ceramide. The simple explanation would be that the cost per
sample using MS is still much greater than the cost for DAG
kinase assays and immunodetection. MS requires specialized
equipment and knowledge in the technique which may not
be available to all laboratories. Regardless, MS is still the
most accurate technique currently available for ceramide
quantiﬁcation.
6. Conclusion
The area of lipid research is continually gaining momentum.
With the improvement of sensitive quantiﬁcation methods
such as MS, it is now possible to accurately measure the
levels of ceramides. When testing the levels of ceramides, all
detectable species of ceramides (and not only a selection of
ceramide species) have to be assessed to fully explore the
role of these important mediators in various cellular and
molecular mechanisms of gene expression regulation and
CF physiology. Ceramides are important in the immune
responseanditispossiblethatdiﬀerentspecieshavediﬀerent
roles. The results in the area of CF are contradicting due to
the animal models used and methods of ceramide detection.
Certain steps can be undertaken to resolve these issues such
as the use of internal standards and clear MS protocols
should be reported. Most importantly, MS should be made
the gold standard for ceramide analysis since the DAG kinase
assays and the use of antibodies are known to not be reliable
methods.However,despitecontractingresults,theanalysisof
ceramide levels remains an important subject to investigate
in CF using methods which are likely to generate the most
reliable results possible.
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